|[September 27, 2013]
The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against Prosensa Holding NV - RNA
NEW YORK --(Business Wire)--
The Rosen Law Firm, P.A. announces that it has commenced an
investigation into allegations that Prosensa Holding NV (NASDAQ:RNA) may
have violated federal securities laws by issuing false and misleading
statements to investors about its business and financial condition.
Prosensa Holding NV is a biotechnology company that develops ribonucleic
acid-modulating, or RNA-modulating, therapeutics for the treatment of
genetic disorders. The Company focuses on neuromuscular and
neurodegenerative disorders, including Duchenne muscular dystrophy
("DMD"), myotonic dystrophy and Huntington's disease. The Company's lead
product candidate is drisapersen, which aims to treat DMD.
The investigation relates to allegations that the Compny's Registration
Statement and Prospectus issued in connection with its initial public
offering on June 28, 2013 were materially false and misleading.
Specifically, the investigation focuses on allegations that the Prosensa
misrepresented or failed to disclose material facts concerning the
efficacy of drisapersen and its prospects for marketing and regulatory
The Rosen Law Firm is preparing a securities class action lawsuit on
behalf of Prosensa investors. If you purchased Prosensa stock please
visit the website at http:/rosenlegal.com
to join the class action. You may also contact Phillip Kim, Esq. or
Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via
e-mail at firstname.lastname@example.org
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
[ Back To Technology News's Homepage ]